People who took prescription medications for hypertension were less likely than others to develop amyotrophic lateral sclerosis.
At Duke University, researchers discussed how injected stem cells might be tracked and used to treat neurodegenerative diseases.
Aβ and other pathogenic proteins may cause neurodegenerative disease by spreading throughout the brain like infectious diseases spread through populations, according to a new mathematical model.
Whether by themselves or in the company of mutations that cause frontotemporal dementia, microRNAs may play a hand in driving disease.
At ICFTD, researchers proposed new genes and explored genetic differences that contribute to the vast diversity of FTD clinical presentations.
In debating how C9ORF72 causes neurodegeneration, researchers struggle to connect cell-culture results with divergent patterns of human disease.
Variants in the genome that increase the risk for Alzheimer’s also lower the age of onset.
In a two-year study, a heaping dose of vitamin B did nothing to sharpen cognition in people over 65, casting further doubt on the supplement’s ability to stave off dementia.
Stem cells have not yet been tried in a clinical study for Alzheimer’s disease, but that may be about to change. At a Duke symposium, researchers discussed the move toward trials and barriers that remain.
You can add a shortcut to Alzforum.org right on your iPhone or iPad home screen. Simply open Safari (Apple’s default browser) and navigate to the Alzforum homepage. Tap the "share" button on the bottom of the screen and select "Add to Home Screen." To confirm the shortcut, select “Add” in the upper right-hand corner. An icon will be placed on your home screen giving you quick access to Alzforum.org. Happy browsing!
First results from the Genetic FTD Initiative, and the advance of an HDAC inhibitor drug into Phase 2, made big splashes at the ICFTD conference held last month in Vancouver, Canada. Five hundred and ninety scientists from 30 countries met to exchange the latest clinical and scientific news on the diseases that make up FTLD. Multicenter cohort studies in Europe and North America reinforced the sense that there is a community spirit that may allow a common approach to how to develop therapies. Frontotemporal lobar degeneration can start in myriad ways—with social disinhibition, overeating, halting speech, or even odd misperceptions of pain or cold—but it always ends in dementia. Attendees said that the FTD field is poised for rapid progress. Read Jessica Shugart and Gabrielle Strobel's coverage.
- Benjamin Wolozin on Angiotensin-Converting Enzyme Inhibitors and Amyotrophic Lateral Sclerosis Risk: A Total Population-Based Case-Control Study.
- Dawn Kuzma on Too Hot, Too Cold, or Just Wrong? Physiology Links Behavior to Circuits in FTD
- Markus Damme, Thomas Reinheckel and Paul Saftig on Does Novel Tau Protease Promote Pathology?
- A. David Smith on Results of 2-year vitamin B treatment on cognitive performance: Secondary data from an RCT.
- Gregory Cole on Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults.
- Lucia Banci on Aggregation propensities of superoxide dismutase G93 hotspot mutants mirror ALS clinical phenotypes.
- Jean-Charles Lambert on Association of Brain DNA Methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 With Pathological Diagnosis of Alzheimer Disease.